Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Selpercatinib, the first drug in its class, shrank tumors in over two thirds of previously treated patients.
Tests like the one approved this week can show who is likely to be immune, but it’s not yet clear how long such immunity lasts.
Children are exposed to controlled amounts of Palforzia until they can tolerate the dosage needed to avoid severe allergic reactions.
Acting Commissioner Ned Sharpless will return to lead the National Cancer Institute.
The new indication is for prevention of sexually transmitted HIV, with the exception of transmission via receptive vaginal sex.
AACR report highlights progress in preventing and treating cancer—including 27 new drug approvals last year—but disparities persist.
Off-label drug use for respiratory infections, asthma or mental health disorders in children is on the rise.
Pretomanid triple therapy cuts the length of treatment from 18 months to six months.
Previously, tests were approved only for use with genital or urine samples.
Eighty percent of medications that receive accelerated approval don’t extend overall survival.
Imbruvica plus Gazyva is the first chemotherapy-free regimen for chronic lymphocytic leukemia.
Four out of 10 FDA workers are sidelined.
Did you know there’s a preventive vaccine for the world’s most common STI?
Human papillomavirus vaccine can prevent cervical, anal and oral cancers.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
Lucemyra is approved to treat the symptoms of opioid withdrawal for 14 days.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.